Relmada Therapeutics (RLMD) Net Equity Issued and Repurchased (2012 - 2022)

Relmada Therapeutics (RLMD) has reported Net Equity Issued and Repurchased for 7 consecutive years, with $13.1 million the latest figure, recorded in Q2 2022.

• In Q2 2022, Net Equity Issued and Repurchased changed N/A year-over-year to $13.1 million; the TTM figure through Dec 2022 stood at $42.7 million (down 73.48% YoY), while the FY2025 annual figure was $93.6 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased fell to $13.1 million in Q2 2022 per RLMD's latest filing, from $29.6 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $161.2 million in Q4 2021 and bottomed at -$8.2 million in Q4 2018.
• Historically, Net Equity Issued and Repurchased has averaged $20.2 million across 5 years, with a median of $1.7 million in 2019.
• Annual changes were most pronounced in 2020 — Net Equity Issued and Repurchased slumped 100.29% — and 2021, when it surged 646222.49%.
• Relmada Therapeutics' Net Equity Issued and Repurchased stood at -$8.2 million in 2018, then soared by 262.89% to $13.4 million in 2019, then plunged by 100.19% to -$24953.0 in 2020, then soared by 646222.49% to $161.2 million in 2021, then plunged by 91.85% to $13.1 million in 2022.
• Business Quant data shows RLMD's Net Equity Issued and Repurchased at $13.1 million in Q2 2022, $29.6 million in Q1 2022, and $161.2 million in Q4 2021.